The U.S. Food and Drug Administration has granted premarket approval for the NeuroPace® RNS® System to treat medically refractory epilepsy.

The RNS System is a novel, implantable therapeutic device that delivers responsive neurostimulation, an advanced technology designed to detect abnormal electrical activity in the brain and respond by delivering imperceptible levels of electrical stimulation to normalize brain activity before an individual experiences seizures.

Read more at BusinessWire here
FDA’s press release is available here

Post to Twitter Post to Yahoo Buzz Post to Delicious Post to Digg Post to Facebook Post to Google Buzz Post to LinkedIn Post to Slashdot Post to StumbleUpon Post to Technorati